MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $145.75 (23.89% upside)

Analysts' Ratings History for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetActions
5/12/2016Roth CapitalReiterated RatingBuy$147.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016StephensInitiated CoverageOverweight$150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016SidotiInitiated CoverageBuy$140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016HC WainwrightInitiated CoverageBuy$146.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2015Deutsche BankDowngradeBuy -> Hold$94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Craig HallumReiterated RatingBuy$90.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2016Q415$0.65$0.66$24.71 million$21.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.40$1.81$17.00 million$18.42 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115$0.27$0.33$13.50 million$14.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2015Q414$0.60$0.60$23.88 million$23.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314$0.31$0.36$14.60 million$15.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Ligand Pharmaceuticals (NASDAQ:LGND)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.44$0.46$0.45
Q2 20161$0.54$0.54$0.54
Q3 20162$0.62$0.63$0.63
Q4 20162$1.08$1.16$1.12
(Data provided by Zacks Investment Research)
Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ligand Pharmaceuticals (NASDAQ:LGND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Ligand Pharmaceuticals (NASDAQ:LGND)
DateHeadline
06/27/16 09:17 AMLigand Pharmaceuticals (NASDAQ:LGND) Shorts Decreased by 0.86% After Short Covering - Press Telegraph
06/21/16 09:26 AMGurus Invest in Top Biotechnology Stocks - GuruFocus.com
06/07/16 05:07 PMNovartis AG (NYSE:NVS), Eisai Co., Ltd (OTCMKTS:ESALY) To Cooperate In Cancer Drugs Marketing In The U.S. - Market Exclusive
06/07/16 04:41 PMETF’s with exposure to Ligand Pharmaceuticals, Inc. : June 7, 2016 -
06/04/16 04:58 PMState Street Corp Decreased Stake in Lockheed Martin Corp (NYSE:LMT) by $127.86 Million as Shares Rose - CCH Daily News
06/04/16 07:42 AMLigand Pharmaceuticals Inc. (LGND) Director John W. Kozarich Sells 1000 Shares - Let Me Know About This
06/03/16 05:18 PMMacquarie Group LTD Decreased Stake in Edison International (NYSE:EIX) by $44.91 Million as Shares Rose - CCH Daily News
06/02/16 07:19 AMLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : June 2, 2016 -
05/31/16 09:06 AMLigand Pharmaceuticals Inc (LGND): David M. Knott of Dorset Management Resigned from the Board - Insider Monkey (blog) - Insider Monkey (blog)Ligand Pharmaceuticals Inc (LGND): David M. Knott of Dorset Management Resigned from the BoardInsider Monkey (blog)David M. Knott's Dorset Managment, recently filed an amended 13D, with the US SEC, reporting David Knott's resignation from the board of the directors of Ligand Pharmaceuticals Inc (NASDAQ:LGND), for reasons that are unconnected to the company.and more »
05/28/16 07:45 PMTurner Investments LP Increased Ligand Pharmaceuticals INC (NASDAQ:LGND) by $4.39 Million as Shares Rose - CCH Daily News - Turner Investments LP Increased Ligand Pharmaceuticals INC (NASDAQ:LGND) by $4.39 Million as Shares RoseCCH Daily NewsTurner Investments Lp increased its stake in Ligand Pharmaceuticals Inc (NASDAQ:LGND) by 205.15% based on its latest 2016Q1 regulatory filing with the SEC. Turner Investments Lp bought 41,030 shares as the company's stock rose 4.51% with the market ...Are Analysts Bullish Ligand Pharmaceuticals Inc. (NASDAQ:LGND) After Last Week?Franklin IndependentLigand Pharmaceuticals Incorporated (NASDAQ:LGND) moved up 0.70%: Rockwell Collins Inc. (NYSE:COL), MAG ...Benchmark MonitorCurrent Price Targets For Ligand Pharmaceuticals Incorporated (LGND)Risers & Fallersall 7 news articles »
05/26/16 09:15 PMIs Best Biotech Stock Buy Now, GILD Or ? You Pick - Here is an alternative set of prospective price range potentials, with indications of how the today's outlook has fared in the marketplace following many prior experiences for Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The same persuasive factors are at ...
05/25/16 03:02 PMLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
05/20/16 01:44 AMInsider Selling: Ligand Pharmaceuticals Inc. (NASDAQ:LGND)'s Director of Accounting Melanie Herman Sold 334 shares - Wall Street Hints and News - Insider Selling: Ligand Pharmaceuticals Inc. (NASDAQ:LGND)'s Director of Accounting Melanie Herman Sold 334 sharesWall Street Hints and NewsAfter the publishing of a public document filled with Security and Exchange Commission; an important and highly notable insider trade became apparent. The Director of Accounting of Ligand Pharmaceuticals Inc, Melanie Herman; made a huge trade in the ...
05/18/16 12:04 PMLIGAND PHARMACEUTICALS INC Financials -
05/13/16 08:59 PMStocks within Traders Screening: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) , TrovaGene, Inc. (NASDAQ ... - Street Updates - Stocks within Traders Screening: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) , TrovaGene, Inc. (NASDAQ ...Street UpdatesOn 5/12/2016, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ended trading session higher at $116.62 with +0.21%. The company traded a volume of 501.24 thousand shares as comparison to average volume of 417.21 thousand shares. During the ...
05/11/16 09:12 PMLigand Pharmaceuticals To Participate In BOA Merrill Lynch Conference At 2:20 PM - Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages. Please note that once you make your selection, it will apply to all future visits to NASDAQ.com. If ...
05/09/16 02:34 PMETF’s with exposure to Ligand Pharmaceuticals, Inc. : May 9, 2016 -
05/09/16 07:16 AMLIGAND PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and -
05/08/16 11:42 PMEarnings Per Share for Ligand Pharmaceuticals Inc. (LGND) Projected to Decline - B.O.D.Y Confidential - Earnings Per Share for Ligand Pharmaceuticals Inc. (LGND) Projected to DeclineB.O.D.Y ConfidentialWall Street await Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to release earnings on May, 9. Analysts forecast earnings per share of $0.46, up exactly $0.26 or 130.00% from 2014's $0.2 EPS. The expected LGND's profit could reach $9.65M giving the stock ...Ligand Pharmaceuticals (NASDAQ:LGND) Short Interest Decreased By 5.63%Franklin Independentall 3 news articles »
05/07/16 03:06 AMLigand (LGND) Tops Q1 Earnings, Revenues, Updates View - Nasdaq - Web Breaking NewsLigand (LGND) Tops Q1 Earnings, Revenues, Updates ViewNasdaqLigand Pharmaceuticals Inc.LGND reported first quarter 2016 earnings of 79 cents per share (including the impact of stock-based compensation expense), well above the Zacks Consensus Estimate of 46 cents per share and the year-ago earnings of 19 cents ...Ligand Pharmaceuticals Inc. (LGND) Issues Earnings Results, Beats Expectations By $0.30 EPSWeb Breaking NewsLigand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : John W Kozarich Sells 1000 SharesMarket DigestLigand Pharmaceuticals Q1 Adjusted Earnings BeatBenzingaB.O.D.Y Confidential -RTT News -Sonoran Weekly Reviewall 22 news articles »
05/05/16 11:21 AMLigand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/05/16 08:36 AMLigand (LGND) Tops Q1 Earnings, Revenues, Updates View -
05/04/16 09:35 PMLigand Pharmaceuticals Inc Q1 Income Rises 205% - (RTTNews.com) - Ligand Pharmaceuticals Inc ( LGND) released earnings for its first quarter that climbed compared to the same period last year. The company said its bottom line totaled $20.99 million, or $0.97 per share. This was higher than $6.89 million ...
05/04/16 09:09 AMIBD 50: Ligand Pharma Beats Q1 Estimates, Buys Device Royalties -
05/04/16 07:40 AMLigand Pharmaceuticals Q1 Adjusted Earnings Beat - Ligand Pharmaceuticals Inc. (NASDAQ: LGND) reported net income attributable to its shareholders of $6.61 million or $0.30 a share, which was significantly higher than $754 thousand or $0.04 a share in the year-ago quarter. However, excluding special items, its adjusted earnings would have more than tripled to $0.97 a share from $0.30 a share in the same quarter last year. Ligand's total revenues also doubled to $29.6 million from $14.6 million in the previous year quarter. Both earnings and revenue convincingly ...Full story available on Benzinga.com
05/04/16 06:56 AMLigand (LGND) Beats Q1 Earnings and Revenue Estimates -
05/04/16 06:07 AMQ1 2016 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open -
05/04/16 05:21 AMLigand tops 1Q revenue forecasts -
05/04/16 05:17 AMLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement -
05/04/16 05:00 AMLigand Reports First Quarter 2016 Financial Results - [Business Wire] - Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2016, and provided an operating forecast and program updates.
05/04/16 04:59 AMLigand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million - [Business Wire] - Ligand Pharmaceuticals Incorporated announces the acquisition of economic rights to multiple programs owned by CorMatrix®. Ligand will pay $17.5 million and in return will receive a portion of revenue from CorMatrix’s existing marketed products and will have the right to receive future synthetic royalties from potential future products.
05/02/16 10:09 AMLigand (LGND) Q1 Earnings: What's in Store for the Stock? -
04/29/16 03:01 PMLigand Pharma Adds Tech, Grows On Partners’ Success -
04/27/16 05:18 AMLigand Pharmaceuticals (NASDAQ:LGND) Short Interest Decreased By 6.69% - The Post - Ligand Pharmaceuticals (NASDAQ:LGND) Short Interest Decreased By 6.69%The PostThe Delaware-based Ashford Capital Management Inc has invested 2.64% in the stock. First Light Asset Management Llc, a Minnesota-based fund reported 56,818 shares. Out of 7 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 rate it a “Buy”, ...and more »
04/23/16 01:41 AMLigand Pharmaceuticals (NASDAQ:LGND) Sellers Covered 6.69% of Their Shorts - The Post - Ligand Pharmaceuticals (NASDAQ:LGND) Sellers Covered 6.69% of Their ShortsThe PostThe short interest to Ligand Pharmaceuticals's float is 27.35%. The stock increased 1.77% or $2.27 during the last trading session, hitting $130.37. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has risen 34.64% since September 16, 2015 and is uptrending.and more »
04/19/16 05:17 AMLigand Pharmaceuticals (NASDAQ:LGND) Short Interest Decreased By 6.69% - RiversideGazette.com - Ligand Pharmaceuticals (NASDAQ:LGND) Short Interest Decreased By 6.69%RiversideGazette.comLigand Pharmaceuticals Inc. (NASDAQ:LGND) has risen 33.45% since September 10, 2015 and is uptrending. It has outperformed by 26.87% the S&P500. Ligand Pharmaceuticals Incorporated is a biotechnology firm that operates with a business model ...
04/16/16 12:20 AMLigand Pharmaceuticals Inc (NASDAQ:LGND) near 52-week high, short interest stable - Street Report - Washington News WireLigand Pharmaceuticals Inc (NASDAQ:LGND) near 52-week high, short interest stableStreet ReportLigand Pharmaceuticals Inc (NASDAQ:LGND) (TREND ANALYSIS) shares were traded with no significant volume change. The stock closed last trading session at $124.01, up by 2.13%, with a volume of 557,295 shares against an average amount for the last ...Ligand Pharmaceuticals Inc. (LGND) Downgraded by Zacks Investment ResearchWashington News WireRS Investment Management Co. LLC Has $118149000 Position in Ligand Pharmaceuticals Inc. (LGND)The Vista VoiceLigand Pharmaceuticals Inc. (LGND) Now Covered by StephensMas Market NewsEquities.comall 6 news articles »
04/15/16 05:52 PMBRIEF-Ligand Pharma reports 39.8 pct active stake in Viking Therapeutics - * Ligand Pharmaceuticals Incorporated reports 39.8 pct active stake in Viking Therapeutics as of April 13, 2016 - sec filing
04/13/16 09:32 PMStephens Calls Ligand 'Unique,' Sees $150/Share Coming By 2017 - Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a unique biotech play that offers long-term staged growth profile, according to a note from Stephens, which initiated coverage of the stock with an Overweight (Volatile) rating. The brokerage has $150 price ...
04/12/16 02:33 AMDorfman: Alaska Air, Delta and NVR Make the 30-30 Club - Biotechs Four biotech stocks are in the club: Abiomed Inc. (ABMD), Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD) and Ligand Pharmaceuticals (LGND). My preference goes to Gilead, which has more than two dozen drugs already on the market and a diverse ...
04/09/16 02:40 AMLigand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It - The European Commission [EC] has expanded the label for Revolade [Promacta], developed by Ligand Pharmaceuticals Inc. (NASDAQ: LGND) partner Novartis AG (ADR) (NYSE: NVS), by approving the drug for children older than 1 year with chronic ITP. Roth Capital ...
04/08/16 07:27 AMWill Ligand Pharmaceuticals (LGND) Continue to Surge Higher? -
04/08/16 02:45 AMLigand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : John W Kozarich Sells 5000 Shares - Everything HUDSON - Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : John W Kozarich Sells 5000 SharesEverything HUDSONLigand Pharmaceuticals Inc (LGND): John W Kozarich , director of Ligand Pharmaceuticals Inc sold 5,000 shares on Apr 6, 2016. The Insider selling transaction was disclosed on Apr 7, 2016 to the Securities and Exchange Commission. The shares were sold ...Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes ItBenzingaThe Insider and director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), John Kozarich, Unloaded 5000 SharesStock CallerInsider Selling: Ligand Pharmaceuticals Inc. (LGND) Director Sells 5000 Shares of StockWeb Breaking NewsRiversideGazette.com -The Duncan Independent (press release) (blog) -Share Trading Newsall 7 news articles »
04/07/16 08:00 AMRevolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP - [Business Wire] - Ligand Pharmaceuticals Incorporated announces that the European Commission has approved Revolade® , a Novartis product, for the treatment of pediatric chronic immune thrombocytopenic purpura patients who are refractory to other treatments (e.g.
04/07/16 03:04 AMLigand Pharmaceuticals Inc. (NASDAQ:LGND) Receives Consensus Recommendation of “Buy” from Analysts - MicroCap Magazine - The Vista VoiceLigand Pharmaceuticals Inc. (NASDAQ:LGND) Receives Consensus Recommendation of “Buy” from AnalystsMicroCap MagazineLigand Pharmaceuticals logo Shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. Two investment ...Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Receives Consensus Recommendation of "Buy" from AnalystsThe Vista VoiceEarnings View for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)RiversideGazette.comall 4 news articles »
04/02/16 08:45 PMOberweis Asset Management Inc buys $10 Million stake in Ligand Pharmaceuticals (LGND) - SCSUCollegian - Oberweis Asset Management Inc buys $10 Million stake in Ligand Pharmaceuticals (LGND)SCSUCollegianLigand Pharmaceuticals (LGND) : Oberweis Asset Management Inc scooped up 5,760 additional shares in Ligand Pharmaceuticals during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of ...and more »
03/31/16 08:51 PMProShare Advisors LLC Purchases 1869 Shares of Ligand Pharmaceuticals Inc. (LGND) - MicroCap Magazine - MicroCap MagazineProShare Advisors LLC Purchases 1869 Shares of Ligand Pharmaceuticals Inc. (LGND)MicroCap MagazineLigand Pharmaceuticals logo ProShare Advisors LLC boosted its stake in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 10.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).Sei Investments Co. Has $3097000 Stake in Ligand Pharmaceuticals Inc. (LGND)South Florida Hedge Fund ManagersPublic Sector Pension Investment Board Sells 7100 Shares of Ligand Pharmaceuticals Inc. (LGND)Financial Market NewsLigand Pharmaceuticals (NASDAQ:LGND) Sellers Increased By 1.56% Their ShortsRiversideGazette.comHints News Network -The Duncan Independent (press release) (blog) -Benchmark Monitorall 11 news articles »
03/31/16 08:51 PMNationwide Fund Advisors invests in Ligand Pharmaceuticals Inc. (LGND) Shares - MicroCap Magazine - MicroCap MagazineNationwide Fund Advisors invests in Ligand Pharmaceuticals Inc. (LGND) SharesMicroCap MagazineLigand Pharmaceuticals logo Nationwide Fund Advisors raised its position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 183.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund ...Institutional Investors Sentiment Indicator of Ligand Pharmaceuticals Inc (NASDAQ:LGND) Increases in 2015 Q3Franklin IndependentLigand Pharmaceuticals Incorporated (NASDAQ:LGND): Analysts Take on EarningsUptick AnalystBlue Clay Capital Management Lowers stake in Ligand Pharmaceuticals (LGND)SCSUCollegianEverything HUDSON -Stock Transcriptall 6 news articles »
03/22/16 08:05 AMGilead and 4 Other Buy Stocks in the Biotech Industry -
03/15/16 04:35 PM5 Big-Name Medical Stocks Show Notable Chart Action -
About Ligand Pharmaceuticals

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LGND
  • CUSIP: 53220K50
Key Metrics:
  • Previous Close: $117.64
  • 50 Day Moving Average: $117.16
  • 200 Day Moving Average: $108.16
  • P/E Ratio: 9.68
  • P/E Growth: 0.76
  • Market Cap: $2.45B
  • Current Quarter EPS Consensus Estimate: $3.30 EPS
Additional Links:
Ligand Pharmaceuticals (NASDAQ:LGND) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha